| scholarly article | Q13442814 |
| P50 | author | David A. Sack | Q57934978 |
| P2093 | author name string | R Walker | |
| A Louis Bourgeois | |||
| Andrea Feller | |||
| Barbara DeNearing | |||
| Clayton Harro | |||
| Subhra Chakraborty | |||
| Michael J Darsley | |||
| Charlotte Buchwaldt | |||
| P2860 | cites work | Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention | Q24530558 |
| Diarrheagenic Escherichia coli | Q24533466 | ||
| Global, regional, and national causes of child mortality in 2008: a systematic analysis | Q28282386 | ||
| Prolonged episodes of acute diarrhea reduce growth and increase risk of persistent diarrhea in children | Q30430450 | ||
| Childhood stunting: measuring and stemming the staggering costs of inadequate water and sanitation | Q30432780 | ||
| Enteric infections, diarrhea, and their impact on function and development | Q30443288 | ||
| IS1414, an Escherichia coli insertion sequence with a heat-stable enterotoxin gene embedded in a transposase-like gene | Q33591956 | ||
| Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins | Q33755999 | ||
| Phenotypic diversity of enterotoxigenic Escherichia coli strains from a community-based study of pediatric diarrhea in periurban Egypt | Q33962543 | ||
| Safety and immunogenicity of two different lots of the oral, killed enterotoxigenic escherichia coli-cholera toxin B subunit vaccine in Israeli young adults | Q34007642 | ||
| Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans | Q34008614 | ||
| Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults | Q34334202 | ||
| Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I | Q34334284 | ||
| Vaccines against enterotoxigenic Escherichia coli | Q34594874 | ||
| Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. | Q34786549 | ||
| Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines | Q35271174 | ||
| Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli | Q35689012 | ||
| Disease burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community in Bangladesh | Q35949719 | ||
| Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation. | Q36172686 | ||
| Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea | Q36183417 | ||
| Synergistic protective effect of antibodies against Escherichia coli enterotoxin and colonization factor antigens. | Q36334871 | ||
| Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease | Q36708480 | ||
| Economic aspects of travelers' diarrhea | Q37111995 | ||
| Estimating child mortality due to diarrhoea in developing countries | Q37113098 | ||
| Serologic correlates of protection against enterotoxigenic Escherichia coli diarrhea | Q39383873 | ||
| Double-blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers' diarrhea (preliminary report). | Q39591612 | ||
| Generation and characterization of a live attenuated enterotoxigenic Escherichia coli combination vaccine expressing six colonization factors and heat-labile toxin subunit B. | Q39657777 | ||
| Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and toxins of enterotoxigenic Escherichia coli | Q39820829 | ||
| In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units | Q40365149 | ||
| Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh | Q40404190 | ||
| Enteroaggregative Escherichia coli heat-stable enterotoxin is not restricted to enteroaggregative E. coli | Q41491528 | ||
| A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC. | Q42542793 | ||
| Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers | Q42542916 | ||
| Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults | Q43282979 | ||
| Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine | Q50183477 | ||
| Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. | Q53588316 | ||
| Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. | Q54442796 | ||
| Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. | Q55043303 | ||
| Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial | Q57926913 | ||
| Future directions for research on enterotoxigenic Escherichia coli vaccines for developing countries | Q57937554 | ||
| Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers | Q73476093 | ||
| Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli | Q74302631 | ||
| Safety, Immunogenicity, and Protective Efficacy of the Whole-Cell/Recombinant B Subunit (WC/rBS) Oral Cholera Vaccine Against Travelers' Diarrhea | Q77552807 | ||
| Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response | Q84066281 | ||
| P433 | issue | 12 | |
| P921 | main subject | Escherichia coli | Q25419 |
| enterotoxigenic Escherichia coli | Q265214 | ||
| placebo | Q269829 | ||
| attenuated vaccine | Q1810913 | ||
| P304 | page(s) | 2118-2127 | |
| P577 | publication date | 2011-10-12 | |
| P1433 | published in | Clinical and Vaccine Immunology | Q5133811 |
| P1476 | title | A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phas | |
| P478 | volume | 18 |
| Q35935738 | A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles |
| Q38284501 | An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children |
| Q91193628 | Booster vaccination with a fractional dose of an oral cholera vaccine induces comparable vaccine-specific antibody avidity as a full dose: A randomised clinical trial |
| Q26865925 | Clinical implications of enteroadherent Escherichia coli |
| Q43867706 | Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein |
| Q40375701 | Colonization Factors in Enterotoxigenic Escherichia coli Strains in Travelers to Mexico, Guatemala, and India Compared with Children in Houston, Texas |
| Q35896237 | Combination vaccines against diarrheal diseases |
| Q35023488 | Conservation and immunogenicity of novel antigens in diverse isolates of enterotoxigenic Escherichia coli. |
| Q27682738 | Crystal structure of enterotoxigenic Escherichia coli colonization factor CS6 reveals a novel type of functional assembly |
| Q35998767 | Current Progress in Developing Subunit Vaccines against Enterotoxigenic Escherichia coli-Associated Diarrhea |
| Q33813634 | Designing vaccines to neutralize effective toxin delivery by enterotoxigenic Escherichia coli. |
| Q42250403 | Development of a fast-dissolving tablet formulation of a live attenuated enterotoxigenic E. coli vaccine candidate |
| Q90029193 | Development of a novel multiplex electrochemiluminescent-based immunoassay to aid enterotoxigenic Escherichia coli vaccine development and evaluations |
| Q44727334 | Different kinetics of circulating antibody-secreting cell responses after primary and booster oral immunizations: a tool for assessing immunological memory |
| Q54201990 | Enterotoxigenic Escherichia coli blood group A interactions intensify diarrheal severity. |
| Q39657777 | Generation and characterization of a live attenuated enterotoxigenic Escherichia coli combination vaccine expressing six colonization factors and heat-labile toxin subunit B. |
| Q35213355 | Genetic fusions of a CFA/I/II/IV MEFA (multiepitope fusion antigen) and a toxoid fusion of heat-stable toxin (STa) and heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC) retain broad anti-CFA and antitoxin antigenicity |
| Q42554197 | Highlights of the 8th International Conference on Vaccines for Enteric Diseases: the Scottish Encounter To Defeat Diarrheal Diseases |
| Q40192692 | Human immune responses against Shigella and enterotoxigenic E. coli: Current advances and the path forward |
| Q38059916 | Immune responses and protection in children in developing countries induced by oral vaccines |
| Q55322314 | Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteers. |
| Q50652449 | Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic Escherichia coli vaccine. |
| Q93088615 | Interrogation of a live-attenuated enterotoxigenic Escherichia coli vaccine highlights features unique to wild-type infection |
| Q53696162 | Intestinal Pathogenic Escherichia coli: Insights for Vaccine Development. |
| Q50861163 | Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country. |
| Q64109788 | Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge |
| Q41715897 | MEFA (multiepitope fusion antigen)-Novel Technology for Structural Vaccinology, Proof from Computational and Empirical Immunogenicity Characterization of an Enterotoxigenic Escherichia coli (ETEC) Adhesin MEFA. |
| Q37545078 | Multiepitope fusion antigen induces broadly protective antibodies that prevent adherence of Escherichia coli strains expressing colonization factor antigen I (CFA/I), CFA/II, and CFA/IV. |
| Q38908041 | Murine immunization with CS21 pili or LngA major subunit of enterotoxigenic Escherichia coli (ETEC) elicits systemic and mucosal immune responses and inhibits ETEC gut colonization |
| Q34349166 | Novel antigens for enterotoxigenic Escherichia coli vaccines |
| Q38032878 | Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans |
| Q35920317 | Protective Enterotoxigenic Escherichia coli Antigens in a Murine Intranasal Challenge Model |
| Q34375210 | Recent advances in understanding enteric pathogenic Escherichia coli. |
| Q41637482 | Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study |
| Q36505159 | The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease |
| Q48008673 | Vaccines for enteric diseases: a meeting summary |
| Q24201328 | Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea |
Search more.